File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/S0168-8278(18)31222-4
- WOS: WOS:000461068602189
- Find via
Supplementary
-
Citations:
- Web of Science: 0
- Appears in Collections:
Conference Paper: Long-term outcomes and significance of HBeAg Seroclearance in Chronic Hepatitis B: Novel Predictive Scores for HCC and HBsAg seroclearance
Title | Long-term outcomes and significance of HBeAg Seroclearance in Chronic Hepatitis B: Novel Predictive Scores for HCC and HBsAg seroclearance |
---|---|
Authors | |
Issue Date | 2018 |
Publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep |
Citation | The International Liver Congress 2018 (ILC 2018), Paris, France, 11–15 April 2018. Abstract Book in Journal of Hepatology, 2018, v. 68 n. Suppl. 1, p. S486-S487, abstract no. FRI-282 How to Cite? |
Abstract | Background and Aims: We aimed to determine the clinical outcomes, the factors and predictive scores for hepatocellular carcinoma (HCC) and hepatitis B surface antigen (HBsAg) seroclearance of a large
cohort of patients undergoing HBeAg seroclearance (ESC). Method: Patients with documented ESC were followed up 3–6 monthly. Baseline characteristics and longitudinal laboratory results were recorded. Predictive scores for HCC (HCC-ESC) and HBsAg seroclearance (HBsAg-ESC) were derived from multivariate Cox regression models.
Results: A total of 723 patients underwent ESC with a median ESC age and follow-up of 36.0 and 18.3 years respectively. Only 3.5% and 3.0% had persistently normal ALT and HBV DNA <2logsIU/ml respectively after ESC. For patients with 100%, 100–90%, 90–50%, 50–10%, 10–0%, and 0% normal ALT after HBeAg seroclearance, the rate of HCC was 4.3%, 2.2%, 3.6%, 3.9%, 17.3%, and 37.2% at 20 years after ESC respectively (p < 0.001). At 20 years after ESC, the cumulative incidence of HCC and HBsAg seroclearance was 7.9% and 13.5% respectively, with an overall survival of 91.5%. ESC age, male sex,
cirrhosis, hypoalbuminemia, viral load, and ALT were significant factors for HCC, whereas ESC age, male sex, viral load, and antiviral therapy were significant factors for HBsAg seroclearance. The HCCESC
score to predict the HCC risk for up to 20 years after ESC was calculated using age (years) + 20*sex (male = 1; female = 0) + 29*cirrhosis (presence = 1; absence = 0) + 5*DNA (logIU/ml) + 31*ALT group
(flares or persistently abnormal ALT = 1; otherwise = 0) + 23*hypoalbuminemia (<39 g/l, presence = 1; absence = 0). With an optimal cut-off of 129, 121, and 114, the AUROC for predicting development of
HCC at 5, 10 and 20 years after HBeAg seroclearance was 0.95, 0.91, and 0.92 respectively. The HBsAg-ESC score to predict HBsAg seroclearance up to 20 years was calculated using age (years) +
15*sex (male = 1; female = 0)−6*DNA (logIU/ml)−40*history of treatment (presence = 1; absence = 0). Using optimal cut-offs of 19, 17, and 12 to predict HBsAg seroclearance at 5, 10, and 20 years after
HBeAg seroclearance were associated with an AUROC of 0.88, 0.84, and 0.74 respectively.
Conclusion: Male gender, older age at ESC, ALT, and higher level of HBV DNA were associated with higher rates of HCC after ESC. HCCESC and HBsAg-ESC predictive scores can determine the likelihood of developing HCC and achieving HBsAg seroclearance. |
Description | Poster Presentation - no. FRI-282 The Congress was hosted by The European Association for the Study of the Liver (EASL) |
Persistent Identifier | http://hdl.handle.net/10722/262206 |
ISSN | 2023 Impact Factor: 26.8 2023 SCImago Journal Rankings: 9.857 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fung, JYY | - |
dc.contributor.author | Cheung, KSM | - |
dc.contributor.author | Wong, DKH | - |
dc.contributor.author | Mak, LY | - |
dc.contributor.author | To, WP | - |
dc.contributor.author | Seto, WKW | - |
dc.contributor.author | Lai, CL | - |
dc.contributor.author | Yuen, RMF | - |
dc.date.accessioned | 2018-09-28T04:55:10Z | - |
dc.date.available | 2018-09-28T04:55:10Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | The International Liver Congress 2018 (ILC 2018), Paris, France, 11–15 April 2018. Abstract Book in Journal of Hepatology, 2018, v. 68 n. Suppl. 1, p. S486-S487, abstract no. FRI-282 | - |
dc.identifier.issn | 0168-8278 | - |
dc.identifier.uri | http://hdl.handle.net/10722/262206 | - |
dc.description | Poster Presentation - no. FRI-282 | - |
dc.description | The Congress was hosted by The European Association for the Study of the Liver (EASL) | - |
dc.description.abstract | Background and Aims: We aimed to determine the clinical outcomes, the factors and predictive scores for hepatocellular carcinoma (HCC) and hepatitis B surface antigen (HBsAg) seroclearance of a large cohort of patients undergoing HBeAg seroclearance (ESC). Method: Patients with documented ESC were followed up 3–6 monthly. Baseline characteristics and longitudinal laboratory results were recorded. Predictive scores for HCC (HCC-ESC) and HBsAg seroclearance (HBsAg-ESC) were derived from multivariate Cox regression models. Results: A total of 723 patients underwent ESC with a median ESC age and follow-up of 36.0 and 18.3 years respectively. Only 3.5% and 3.0% had persistently normal ALT and HBV DNA <2logsIU/ml respectively after ESC. For patients with 100%, 100–90%, 90–50%, 50–10%, 10–0%, and 0% normal ALT after HBeAg seroclearance, the rate of HCC was 4.3%, 2.2%, 3.6%, 3.9%, 17.3%, and 37.2% at 20 years after ESC respectively (p < 0.001). At 20 years after ESC, the cumulative incidence of HCC and HBsAg seroclearance was 7.9% and 13.5% respectively, with an overall survival of 91.5%. ESC age, male sex, cirrhosis, hypoalbuminemia, viral load, and ALT were significant factors for HCC, whereas ESC age, male sex, viral load, and antiviral therapy were significant factors for HBsAg seroclearance. The HCCESC score to predict the HCC risk for up to 20 years after ESC was calculated using age (years) + 20*sex (male = 1; female = 0) + 29*cirrhosis (presence = 1; absence = 0) + 5*DNA (logIU/ml) + 31*ALT group (flares or persistently abnormal ALT = 1; otherwise = 0) + 23*hypoalbuminemia (<39 g/l, presence = 1; absence = 0). With an optimal cut-off of 129, 121, and 114, the AUROC for predicting development of HCC at 5, 10 and 20 years after HBeAg seroclearance was 0.95, 0.91, and 0.92 respectively. The HBsAg-ESC score to predict HBsAg seroclearance up to 20 years was calculated using age (years) + 15*sex (male = 1; female = 0)−6*DNA (logIU/ml)−40*history of treatment (presence = 1; absence = 0). Using optimal cut-offs of 19, 17, and 12 to predict HBsAg seroclearance at 5, 10, and 20 years after HBeAg seroclearance were associated with an AUROC of 0.88, 0.84, and 0.74 respectively. Conclusion: Male gender, older age at ESC, ALT, and higher level of HBV DNA were associated with higher rates of HCC after ESC. HCCESC and HBsAg-ESC predictive scores can determine the likelihood of developing HCC and achieving HBsAg seroclearance. | - |
dc.language | eng | - |
dc.publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep | - |
dc.relation.ispartof | Journal of Hepatology | - |
dc.relation.ispartof | The International Liver Congress 2018 (ILC 2018) | - |
dc.title | Long-term outcomes and significance of HBeAg Seroclearance in Chronic Hepatitis B: Novel Predictive Scores for HCC and HBsAg seroclearance | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Fung, JYY: jfung@hkucc.hku.hk | - |
dc.identifier.email | Cheung, KSM: cks634@hku.hk | - |
dc.identifier.email | Wong, DKH: danywong@hku.hk | - |
dc.identifier.email | Seto, WKW: wkseto@hku.hk | - |
dc.identifier.email | Lai, CL: hrmelcl@hkucc.hku.hk | - |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | - |
dc.identifier.authority | Fung, JYY=rp00518 | - |
dc.identifier.authority | Wong, DKH=rp00492 | - |
dc.identifier.authority | Seto, WKW=rp01659 | - |
dc.identifier.authority | Lai, CL=rp00314 | - |
dc.identifier.authority | Yuen, RMF=rp00479 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/S0168-8278(18)31222-4 | - |
dc.identifier.hkuros | 292248 | - |
dc.identifier.volume | 68 | - |
dc.identifier.issue | Suppl. 1 | - |
dc.identifier.spage | S486, abstract no. FRI-282 | - |
dc.identifier.epage | S487, abstract no. FRI-282 | - |
dc.identifier.isi | WOS:000461068602189 | - |
dc.publisher.place | Netherlands | - |
dc.identifier.issnl | 0168-8278 | - |